Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Otitis Media-Pipeline Review, H1 2015

Otitis Media-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Otitis Media-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Otitis Media-Pipeline Review, H1 2015', provides an overview of the Otitis Media's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Otitis Media, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Otitis Media and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Otitis Media

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Otitis Media and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Otitis Media products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Otitis Media pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Otitis Media

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Otitis Media Overview 8

Therapeutics Development 9

Pipeline Products for Otitis Media-Overview 9

Pipeline Products for Otitis Media-Comparative Analysis 10

Otitis Media-Therapeutics under Development by Companies 11

Otitis Media-Therapeutics under Investigation by Universities/Institutes 13

Otitis Media-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Otitis Media-Products under Development by Companies 17

Otitis Media-Products under Investigation by Universities/Institutes 18

Otitis Media-Companies Involved in Therapeutics Development 19

Arbor Pharmaceuticals, LLC. 19

BCO Pharma Ltd 20

Cellceutix Corporation 21

ContraFect Corporation 22

Cubist Pharmaceuticals, Inc. 23

GlaxoSmithKline plc 24

Laboratorios SALVAT S.A. 25

Otonomy, Inc. 26

Serum Institute of India Limited 27

Yuhan Corporation 28

Otitis Media-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Combination Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

(fluocinolone acetonide + ciprofloxacin hydrochloride)-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

AR-01-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

BCO-002-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

betahistine hydrochloride-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

brilacidin-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

CF-309-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

ciprofloxacin SR-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

GSK-2189242A-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

P-13-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Recombinant Peptide to Inhibit DNA for Otitis Media and Haemophilus Influenzae Infections-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

SIILPCV-10-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

solithromycin-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

YH-1177-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Otitis Media-Recent Pipeline Updates 55

Otitis Media-Dormant Projects 72

Otitis Media-Product Development Milestones 73

Featured News & Press Releases 73

Sep 29, 2014: SALVAT announces positive top-line results from two Phase III studies of its novel otic antibiotic/steroid combination solution in the treatment of AOMT with Tympanostomy tubes 73

Jul 08, 2014: Otonomy Announces Positive Results from Two Phase 3 Trials of AuriPro in Pediatric Patients Undergoing Ear Tube Placement Surgery 74

May 08, 2014: Otonomy Completes Enrollment of AuriPro Pivotal Studies in Pediatric Patients Undergoing Ear Tube Placement Surgery 74

Feb 24, 2014: Cellceutix Selects Dr. Reddy's Laboratories for Formulation of Brilacidin for Ophthalmic and Otitis Infections 75

Dec 11, 2013: Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery 76

Aug 20, 2013: Otonomy Announces Positive Phase 1b Results for OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery 76

May 28, 2013: Salvat Completes Enrollment Of Phase III Study For New Combination In Acute Otitis Media In Pediatric Patients With Tympanostomy Tubes 77

Oct 29, 2012: Study Suggests New Way to Prevent Recurrent Ear Infections 78

Jun 08, 2011: Otonomy Announces Positive Preclinical Results For OTO-201 79

Dec 30, 2010: 13therapeutics Completes Pre-IND Meeting With FDA 80

Appendix 81

Methodology 81

Coverage 81

Secondary Research 81

Primary Research 81

Expert Panel Validation 81

Contact Us 82

Disclaimer 82

List of Tables

Number of Products under Development for Otitis Media, H1 2015 9

Number of Products under Development for Otitis Media-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Investigation by Universities/Institutes, H1 2015 18

Otitis Media-Pipeline by Arbor Pharmaceuticals, LLC., H1 2015 19

Otitis Media-Pipeline by BCO Pharma Ltd, H1 2015 20

Otitis Media-Pipeline by Cellceutix Corporation, H1 2015 21

Otitis Media-Pipeline by ContraFect Corporation, H1 2015 22

Otitis Media-Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 23

Otitis Media-Pipeline by GlaxoSmithKline plc, H1 2015 24

Otitis Media-Pipeline by Laboratorios SALVAT S.A., H1 2015 25

Otitis Media-Pipeline by Otonomy, Inc., H1 2015 26

Otitis Media-Pipeline by Serum Institute of India Limited, H1 2015 27

Otitis Media-Pipeline by Yuhan Corporation, H1 2015 28

Assessment by Monotherapy Products, H1 2015 29

Assessment by Combination Products, H1 2015 30

Number of Products by Stage and Target, H1 2015 32

Number of Products by Stage and Mechanism of Action, H1 2015 34

Number of Products by Stage and Route of Administration, H1 2015 36

Number of Products by Stage and Molecule Type, H1 2015 38

Otitis Media Therapeutics-Recent Pipeline Updates, H1 2015 55

Otitis Media-Dormant Projects, H1 2015 72

List of Figures

Number of Products under Development for Otitis Media, H1 2015 9

Number of Products under Development for Otitis Media-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 29

Number of Products by Top 10 Targets, H1 2015 31

Number of Products by Stage and Top 10 Targets, H1 2015 32

Number of Products by Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 35

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36

Number of Products by Top 10 Molecule Types, H1 2015 37

Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Arbor Pharmaceuticals, LLC.

BCO Pharma Ltd

Cellceutix Corporation

ContraFect Corporation

Cubist Pharmaceuticals, Inc.

GlaxoSmithKline plc

Laboratorios SALVAT S.A.

Otonomy, Inc.

Serum Institute of India Limited

Yuhan Corporation

Otitis Media Therapeutic Products under Development, Key Players in Otitis Media Therapeutics, Otitis Media Pipeline Overview, Otitis Media Pipeline, Otitis Media Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com